JNJ.N
現在値
149.18USD変化
2.01(+1.37%)出来高
6,627,060本日のレンジ
-
149.6452週レンジ
-
157.00∙ 約20分前の相場を表示しています。
Sept 17 (Reuters) - Johnson & Johnson <JNJ.N>::XWPHARMA - COMPLETED A $40 MILLION SERIES C FINANCING.XWPHARMA - FINANCING WAS LED BY PANACEA VENTURE, WITH PARTICIPATION FROM EXISTING INVESTORS, JOHNSON & JOHNSON INNOVATION.
Sept 15 (Reuters) - Momenta Pharmaceuticals Inc <MNTA.O>::MOMENTA PHARMACEUTICALS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD IN CONNECTION WITH PROPOSED SALE TO JOHNSON & JOHNSON.MOMENTA PHARMACEUTICALS INC - TRANSACTION IS EXPECTED TO CLOSE IN EARLY OCTOBER 2020.
Sept 14 (Reuters) - SpringWorks Therapeutics Inc <SWTX.O>::SPRINGWORKS THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH JANSSEN TO EVALUATE NIROGACESTAT IN COMBINATION WITH TECLISTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SPRINGWORKS THERAPEUTICS - JANSSEN WILL SPONSOR AND CONDUCT PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF COMBINATION.SPRINGWORKS THERAPEUTICS - JANSSEN WILL ASSUME ALL COSTS ASSOCIATED WITH STUDY, OTHER THAN EXPENSES RELATED TO MANUFACTURING OF NIROGACESTAT.SPRINGWORKS THERAPEUTICS - WILL ALSO FORM A JOINT OVERSIGHT COMMITTEE WITH JANSSEN.
Sept 10 (Reuters) - Johnson & Johnson <JNJ.N>::HEALTH CANADA APPROVES TREMFYA (GUSELKUMAB INJECTION), A FIRST-IN-CLASS SELECTIVE INTERLEUKIN (IL)-23 INHIBITOR FOR ACTIVE PSORIATIC ARTHRITIS.
Sept 10 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN SUBMITS APPLICATION SEEKING U.S. FDA APPROVAL OF DARZALEX FASPRO™ (DARATUMUMAB AND HYALURONIDASE-FIHJ) FOR THE TREATMENT OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS.JANSSEN PHARMACEUTICAL COMPANIES - SBLA IS BEING REVIEWED UNDER FDA REAL-TIME ONCOLOGY REVIEW (RTOR) PROGRAM.
Sept 2 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN TO DISCONTINUE PIMODIVIR INFLUENZA DEVELOPMENT PROGRAM.JANSSEN PHARMACEUTICAL -DECISION BASED ON RECENT RESULTS FROM PRE-PLANNED INTERIM ANALYSES OF PIMODIVIR PHASE 3 TRIAL IN HOSPITALIZED PATIENTS WITH INFLUENZA A.JANSSEN - DATA SHOW THAT PIMODIVIR DOES NOT OFFER A BENEFIT ABOVE EXISTING STANDARD OF CARE.JANSSEN - PIMODIVIR PHASE 3 TRIAL IN INFLUENZA A FOUND PIMODIVIR IN COMBINATION WITH SOC WAS VERY UNLIKELY TO DEMONSTRATE ADDED BENEFIT.JANSSEN - STUDY IN HOSPITALIZED PATIENTS WITH INFLUENZA A AND PARALLEL PHASE 3 STUDY OF PIMODIVIR IN OUTPATIENTS WITH INFLUENZA A WILL BE HALTED.
Aug 31 (Reuters) - Johnson & Johnson <JNJ.N>::ENIGMA BIOMEDICAL GROUP SIGNS AGREEMENT TO LICENSE NOVEL NEURO IMAGING BIOMARKERS FROM JANSSEN.ENIGMA BIOMEDICAL GROUP - AGREEMENTS PERMIT EBG TO EVALUATE JANSSEN'S PET LIGANDS.ENIGMA BIOMEDICAL GROUP- IF EVALUATION OF JANSSEN'S PET LIGANDS IS FAVORABLE, GRANT TO CO OF OPTION TO NEGOTIATE EXCLUSIVE LICENSE TO EACH PET LIGAND.
Aug 26 (Reuters) - FDA::FDA - REMOVED BOXED WARNING ABOUT RISK OF LEG & FOOT AMPUTATIONS FOR DIABETES MEDICINE CANAGLIFLOZIN (INVOKANA, INVOKAMET, INVOKAMET XR).
Aug 26 (Reuters) - Johnson & Johnson <JNJ.N>::AETION ADDS STRATEGIC INVESTMENT FROM JOHNSON & JOHNSON INNOVATION - JJDC, INC., EDBI, GREENSPRING ASSOCIATES.AETION - ANNOUNCED A $19 MILLION EXTENSION TO ITS SERIES B FUNDING ROUND.AETION - INVESTMENT BRINGS TOTAL FUNDING TO $94 MILLION SINCE ITS 2015 COMMERCIAL LAUNCH.
Aug 24 (Reuters) - Ligand Pharmaceuticals Inc <LGND.O>::LIGAND ANNOUNCES AMGEN’S KYPROLIS® APPROVED BY FDA AS COMBINATION REGIMEN WITH DARZALEX® AND DEXAMETHASONE IN ONCE- AND TWICE-WEEKLY DOSING REGIMENS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.LIGAND PHARMACEUTICALS - AMGEN HAS SUBMITTED ADDITIONAL MARKETING APPLICATIONS GLOBALLY FOR KYPROLIS.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。